Reviva Pharmaceuticals Joins Webull Corporate Communications Service Platform

May 19, 2023 | Press Releases

CUPERTINO, Calif., May 19, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in May 2023

May 18, 2023 | Press Releases

CUPERTINO, Calif., May 18, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 15, 2023 | Press Releases

– Topline data for pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected mid-2023 – – Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced...

Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference

May 12, 2023 | Press Releases

CUPERTINO, Calif., May 12, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data

May 11, 2023 | Press Releases

Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model IND submission for brilaroxazine lipogel in psoriasis expected in 2024 Reviva has filed composition of matter...